keyword
MENU ▼
Read by QxMD icon Read
search

Medication management therapy pharmacogenomics

keyword
https://www.readbyqxmd.com/read/27352986/proprotein-convertase-subtilisin-kexin-type-9-pcsk9-inhibitors-present-perspectives-and-future-horizons
#1
REVIEW
K Yadav, M Sharma, K C Ferdinand
AIMS: Our comprehensive review highlights the drug development and pharmacogenomics leading to the recent approval of PCSK9 inhibitors. We also review the anticipated future advances into the uses of PCSK9 inhibition. BACKGROUND: Despite the present advances in pharmacotherapy, atherosclerotic cardiovascular disease (ASCVD) remains the leading cause of mortality worldwide. Low density lipoprotein-cholesterol (LDL-C) lowering is the primary target for ASCVD risk reduction, showing demonstrable benefits in mortality...
October 2016: Nutrition, Metabolism, and Cardiovascular Diseases: NMCD
https://www.readbyqxmd.com/read/27262358/recent-patents-for-the-treatment-of-asthma
#2
David El-Qutob, Isabela Raducan
: Background Despite adequate adherence and completion of anti-asthmatic treatment, many patients remain poorly controlled or uncontrolled. Asthma management is based on the use of medication to reverse the bronchial obstruction and eliminate the airway inflammation. New drug development is expected in the future as a consequence of discoveries in the pathophysiology and mechanisms of asthma. Currently, a good and effective set of treatments is available for these diseases. However, the search for new treatment modalities to improve the currently available is especially important for those patients unresponsive to current therapy...
June 3, 2016: Recent Patents on Inflammation & Allergy Drug Discovery
https://www.readbyqxmd.com/read/27143951/potential-utility-of-precision-medicine-for-older-adults-with-polypharmacy-a-case-series-study
#3
Joseph Finkelstein, Carol Friedman, George Hripcsak, Manuel Cabrera
Pharmacogenomic (PGx) testing has been increasingly used to optimize drug regimens; however, its potential in older adults with polypharmacy has not been systematically studied. In this hypothesis-generating study, we employed a case series design to explore potential utility of PGx testing in older adults with polypharmacy and to highlight barriers in implementing this methodology in routine clinical practice. Three patients with concurrent chronic heart and lung disease aged 74, 78, and 83 years and whose medication regimen comprised 26, 17, and 18 drugs, correspondingly, served as cases for this study...
2016: Pharmacogenomics and Personalized Medicine
https://www.readbyqxmd.com/read/27108830/good-clinical-practice-guide-for-opioids-in-pain-management-the-three-ts-titration-trial-tweaking-tailoring-transition-tapering
#4
Flaminia Coluzzi, Robert Taylor, Joseph V Pergolizzi, Consalvo Mattia, Robert B Raffa
BACKGROUND AND OBJECTIVES: Achieving good clinical practice in the use of opioids as part of a comprehensive pain management regimen can face significant challenges. Despite guidelines from governmental and pain society/organization sources, there are still significant hurdles. A review of some basic tenets of opioid analgesia based on current published knowledge and experiences about this important healthcare imperative is warranted. CONTENT: Consistent with guidelines, the literature supports using the lowest total opioid dose that provides adequate pain control with the fewest adverse effects...
May 2016: Brazilian Journal of Anesthesiology
https://www.readbyqxmd.com/read/27061417/pharmacokinetic-variations-in-cancer-patients-with-liver-dysfunction-applications-and-challenges-of-pharmacometabolomics
#5
REVIEW
Ali Aboel Dahab, Dhia El-Hag, Gamal M Moutamed, Sarah Aboel Dahab, Ramadan Abuknesha, Norman W Smith
PURPOSE: In cancer patients, pharmacokinetic variations between individuals and within individuals due to impairments in organs' function and other reasons such as genetic polymorphisms represent a major problem in disease management, which can result in unpredictable toxicity and variable antineoplastic effects. Addressing pharmacokinetic variations in cancer patients with liver dysfunction and their implications on anticancer and analgesic drugs, in addition to the use of advanced analytical techniques such as metabolomics and pharmacometabolomics, to monitor altered kinetic and discover metabolic biomarkers during therapeutic intervention will help in understanding and reducing pharmacokinetic variations of drugs in cancer patients as a step forward towards personalised medicine...
September 2016: Cancer Chemotherapy and Pharmacology
https://www.readbyqxmd.com/read/26993413/-good-clinical-practice-guide-for-opioids-in-pain-management-the-three-ts-titration-trial-tweaking-tailoring-transition-tapering
#6
Flaminia Coluzzi, Robert Taylor, Joseph V Pergolizzi, Consalvo Mattia, Robert B Raffa
BACKGROUND AND OBJECTIVES: Achieving good clinical practice in the use of opioids as part of a comprehensive pain management regimen can face significant challenges. Despite guidelines from governmental and pain society/organization sources, there are still significant hurdles. A review of some basic tenets of opioid analgesia based on current published knowledge and experiences about this important healthcare imperative is warranted. CONTENT: Consistent with guidelines, the literature supports using the lowest total opioid dose that provides adequate pain control with the fewest adverse effects...
May 2016: Revista Brasileira de Anestesiologia
https://www.readbyqxmd.com/read/26976339/pharmacogenomics-for-personalized-pain-medicine
#7
REVIEW
Tai-Ming Ko, Chih-Shung Wong, Jer-Yuarn Wu, Yuan-Tsong Chen
Pharmacogenomics aims to unravel the way that human genetic variation affects drug efficacy and toxicity. Genome-wide association studies and candidate gene findings suggest that genetic approaches may help choose the most appropriate drug and dosage while preventing adverse drug reactions (ADRs). Pain is an unpleasant feeling that usually results from tissue damage. The management of different types of pain (acute, chronic, inflammatory, neuropathic, or cancer) is challenging. Currently, drug intervention is the first-line therapy for resolving pain...
March 2016: Acta Anaesthesiologica Taiwanica: Official Journal of the Taiwan Society of Anesthesiologists
https://www.readbyqxmd.com/read/26923482/recent-advances-in-biomarkers-and-therapeutic-interventions-for-hepatic-drug-safety-false-dawn-or-new-horizon
#8
Joanna I Clarke, James W Dear, Daniel J Antoine
INTRODUCTION: Drug-induced liver injury (DILI) represents a serious medical challenge and a potentially fatal adverse event. Currently, DILI is a diagnosis of exclusion, and whilst the electronic evaluation of serious drug-induced hepatotoxicity (eDISH) have revolutionised the early assessment of DILI, this model is dependent upon clinical chemistry parameters that lack sensitivity and specificity. DILI management usually consists of initial withdrawal of the suspected drug and, in the case of acetaminophen, administration of specific therapy...
May 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/26801900/pharmacogenetics-driving-personalized-medicine-analysis-of-genetic-polymorphisms-related-to-breast-cancer-medications-in-italian-isolated-populations
#9
Massimiliano Cocca, Davide Bedognetti, Martina La Bianca, Paolo Gasparini, Giorgia Girotto
BACKGROUND: Breast cancer is the most common cancer in women characterized by a high variable clinical outcome among individuals treated with equivalent regimens and novel targeted therapies. In this study, we performed a population based approach intersecting high-throughput genotype data from Friuli Venezia Giulia (FVG) isolated populations with publically available pharmacogenomics information to estimate the frequency of genotypes correlated with responsiveness to breast cancer treatment thus improving the clinical management of this disease in an efficient and cost effective way...
January 22, 2016: Journal of Translational Medicine
https://www.readbyqxmd.com/read/26351205/methodologies-and-experimental-platforms-for-generating-and-analysing-microarray-and-mass-spectrometry-based-omics-data-to-support-p4-medicine
#10
Pietro H Guzzi, Giuseppe Agapito, Marianna Milano, Mario Cannataro
Predictive, preventive, personalized and participatory (P4) medicine is an emerging medical model that is based on the customization of all medical aspects (i.e. practices, drugs, decisions) of the individual patient. P4 medicine presupposes the elucidation of the so-called omic world, under the assumption that this knowledge may explain differences of patients with respect to disease prevention, diagnosis and therapies. Here, we elucidate the role of some selected omics sciences for different aspects of disease management, such as early diagnosis of diseases, prevention of diseases, selection of personalized appropriate and optimal therapies based on molecular profiling of patients...
July 2016: Briefings in Bioinformatics
https://www.readbyqxmd.com/read/25836712/neonatal-medications
#11
REVIEW
Robert M Ward, Justin Stiers, Karen Buchi
Neonatal abstinence syndrome (NAS) is reaching epidemic proportions related to perinatal use of opioids. There are many approaches to assess and manage NAS, including one we have outlined. A standardized approach is likely to reduce length of stay and variability in practice. Circumcision is a frequent, painful procedure performed in the neonatal period. The rationale for providing analgesia is presented as well as a review of methods. Pharmacogenomics and pharmacogenetics have expanded our understanding of diseases and their drug therapy...
April 2015: Pediatric Clinics of North America
https://www.readbyqxmd.com/read/25609992/genomic-based-tools-for-the-risk-assessment-management-and-prevention-of-type-2-diabetes
#12
REVIEW
Katherine A Johansen Taber, Barry D Dickinson
Type 2 diabetes (T2D) is a common and serious disorder and is a significant risk factor for the development of cardiovascular disease, neuropathy, nephropathy, retinopathy, periodontal disease, and foot ulcers and amputations. The burden of disease associated with T2D has led to an emphasis on early identification of the millions of individuals at high risk so that management and intervention strategies can be effectively implemented before disease progression begins. With increasing knowledge about the genetic basis of T2D, several genomic-based strategies have been tested for their ability to improve risk assessment, management and prevention...
2015: Application of Clinical Genetics
https://www.readbyqxmd.com/read/25471684/genetics-of-chronic-post-surgical-pain-a-crucial-step-toward-personal-pain-medicine
#13
REVIEW
Hance Clarke, Joel Katz, Herta Flor, Marcella Rietschel, Scott R Diehl, Ze'ev Seltzer
PURPOSE: Most patients who undergo surgery or experience a traumatic injury suffer from acute pain that subsides once tissues heal. Nevertheless, the pain remains in 15-30% of patients, sometimes for life, and this chronic post-surgical pain (CPSP) can result in suffering, depression, anxiety, sleep disturbance, physical incapacitation, and an economic burden. The incorporation of genetic knowledge is expected to lead to the development of more effective means to prevent and manage CPSP using tools of personalized pain medicine...
March 2015: Canadian Journal of Anaesthesia, Journal Canadien D'anesthésie
https://www.readbyqxmd.com/read/25418285/stratified-medicine-for-the-use-of-antidiabetic-medication-in-treatment-of-type-ii-diabetes-and-cancer-where-do-we-go-from-here
#14
REVIEW
A Emami-Riedmaier, E Schaeffeler, A T Nies, K Mörike, M Schwab
At present, the global diabetes epidemic is affecting 347 million individuals, 90% of whom are diagnosed with type II diabetes mellitus (T2DM). T2DM is commonly treated with more than one type of therapy, including oral antidiabetic drugs (OADs) and agents used in the treatment of diabetic complications. Several pharmacological classes of OADs are currently available for the treatment of T2DM, of which insulin secretagogues (i.e. sulphonylureas and meglitinides), insulin sensitizers [thiazolidinediones (TZDs)] and biguanides are the most commonly prescribed...
February 2015: Journal of Internal Medicine
https://www.readbyqxmd.com/read/25220280/emerging-roles-for-pharmacists-in-clinical-implementation-of-pharmacogenomics
#15
REVIEW
Aniwaa Owusu-Obeng, Kristin W Weitzel, Randy C Hatton, Benjamin J Staley, Jennifer Ashton, Rhonda M Cooper-Dehoff, Julie A Johnson
Pharmacists are uniquely qualified to play essential roles in the clinical implementation of pharmacogenomics. However, specific responsibilities and resources needed for these roles have not been defined. We describe roles for pharmacists that emerged in the clinical implementation of genotype-guided clopidogrel therapy in the University of Florida Health Personalized Medicine Program, summarize preliminary program results, and discuss education, training, and resources needed to support such programs. Planning for University of Florida Health Personalized Medicine Program began in summer 2011 under leadership of a pharmacist, with clinical launch in June 2012 of a clopidogrel-CYP2C19 pilot project aimed at tailoring antiplatelet therapies for patients undergoing percutaneous coronary intervention and stent placement...
October 2014: Pharmacotherapy
https://www.readbyqxmd.com/read/25185987/pharmacogenomics-in-the-intensive-care-unit-focus-on-potential-implications-for-clinical-practice
#16
REVIEW
John M Allen, Shyam Gelot
Critically ill patients often are at high-risk for adverse drug reactions (ADRs), mainly due to alterations in pharmacokinetic and pharmacodynamic (PK/PD) parameters. These PK/PD differences in can also lead to inadequate therapeutic response to many commonly used drugs in this patient population. Frequently in the critically ill patient, medications are utilized based on a "trial-and-error" approach. Furthermore, drug dosing in the critically ill largely remains a "one-size-fits-all" phenomenon, utilizing dosing based on PK studies in healthy volunteers...
2014: Recent Patents on Biotechnology
https://www.readbyqxmd.com/read/25093738/pharmacogenomics-in-heart-failure-where-are-we-now-and-how-can-we-reach-clinical-application
#17
REVIEW
Akinyemi Oni-Orisan, David E Lanfear
Heart failure is becoming increasingly prevalent in the United States and is a significant cause of morbidity and mortality. Several therapies are currently available to treat this chronic illness; however, clinical response to these treatment options exhibit significant interpatient variation. It is now clearly understood that genetics is a key contributor to diversity in therapeutic response, and evidence that genetic polymorphisms alter the pharmacokinetics, pharmacodynamics, and clinical response of heart failure drugs continues to accumulate...
September 2014: Cardiology in Review
https://www.readbyqxmd.com/read/24960519/design-and-anticipated-outcomes-of-the-emerge-pgx-project-a-multicenter-pilot-for-preemptive-pharmacogenomics-in-electronic-health-record-systems
#18
MULTICENTER STUDY
L J Rasmussen-Torvik, S C Stallings, A S Gordon, B Almoguera, M A Basford, S J Bielinski, A Brautbar, M H Brilliant, D S Carrell, J J Connolly, D R Crosslin, K F Doheny, C J Gallego, O Gottesman, D S Kim, K A Leppig, R Li, S Lin, S Manzi, A R Mejia, J A Pacheco, V Pan, J Pathak, C L Perry, J F Peterson, C A Prows, J Ralston, L V Rasmussen, M D Ritchie, S Sadhasivam, S A Scott, M Smith, A Vega, A A Vinks, S Volpi, W A Wolf, E Bottinger, R L Chisholm, C G Chute, J L Haines, J B Harley, B Keating, I A Holm, I J Kullo, G P Jarvik, E B Larson, T Manolio, C A McCarty, D A Nickerson, S E Scherer, M S Williams, D M Roden, J C Denny
We describe here the design and initial implementation of the eMERGE-PGx project. eMERGE-PGx, a partnership of the Electronic Medical Records and Genomics Network and the Pharmacogenomics Research Network, has three objectives: (i) to deploy PGRNseq, a next-generation sequencing platform assessing sequence variation in 84 proposed pharmacogenes, in nearly 9,000 patients likely to be prescribed drugs of interest in a 1- to 3-year time frame across several clinical sites; (ii) to integrate well-established clinically validated pharmacogenetic genotypes into the electronic health record with associated clinical decision support and to assess process and clinical outcomes of implementation; and (iii) to develop a repository of pharmacogenetic variants of unknown significance linked to a repository of electronic health record-based clinical phenotype data for ongoing pharmacogenomics discovery...
October 2014: Clinical Pharmacology and Therapeutics
https://www.readbyqxmd.com/read/24684593/the-role-of-thiopurine-metabolite-monitoring-in-inflammatory-bowel-disease
#19
REVIEW
Lauren Beswick, Antony B Friedman, Miles P Sparrow
Thiopurines are the mainstay of medical management in inflammatory bowel disease (IBD), especially in the maintenance of disease remission. Given the limited IBD armamentarium it is important to optimize each therapy before switching to an alternative drug. Conventional weight based dosing of thiopurines in IBD leads to intolerance or inefficacy in many patients. More recently increased knowledge of their metabolism has allowed for dose optimization using thiopurine metabolite levels, namely 6-thioguanine nucleotides and 6-methylmercaptopurine, with the potential for improved outcomes in patients with IBD...
May 2014: Expert Review of Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/24632932/implementation-of-a-pharmacogenomics-service-in-a-community-pharmacy
#20
Stefanie P Ferreri, Angelo J Greco, Natasha M Michaels, Shanna K O'Connor, Rebecca W Chater, Anthony J Viera, Hawazin Faruki, Howard L McLeod, Mary W Roederer
OBJECTIVE To determine the feasibility of implementing a pharmacogenomics service in a community pharmacy. SETTING A single community pharmacy that is part of a regional chain known for offering innovative pharmacy services. PRACTICE DESCRIPTION Community pharmacists at the project site routinely provide clinical pharmacy services, including medication therapy management, immunizations, point-of-care testing, blood pressure monitoring, and diabetes education. PRACTICE INNOVATION The implementation of a pharmacogenomic testing and interpretation service for the liver isoenzyme cytochrome P450 2C19...
March 2014: Journal of the American Pharmacists Association: JAPhA
keyword
keyword
49003
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"